An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications
Increased proliferation activity of breast cancer cells evaluated by Ki-67 immunohistochemistry, i.e. a high Ki-67 labeling index (Ki-67 LI), may predict better tumor regression in case of neoadjuvant chemotherapy. Despite recommendations for the evaluation of Ki-67 LI, there are variations in metho...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
Springer Netherlands
2013
|
| Sorozat: | PATHOLOGY AND ONCOLOGY RESEARCH
80 No. 3 |
| doi: | 10.1159/000343795 |
| mtmt: | 2151070 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/12829 |
| LEADER | 02767nab a2200241 i 4500 | ||
|---|---|---|---|
| 001 | publ12829 | ||
| 005 | 20200409144903.0 | ||
| 008 | 180201s2013 hu o 0|| zxx d | ||
| 022 | |a 1219-4956 | ||
| 024 | 7 | |a 10.1159/000343795 |2 doi | |
| 024 | 7 | |a 2151070 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Vörös András | |
| 245 | 1 | 3 | |a An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications |h [elektronikus dokumentum] / |c Vörös András |
| 260 | |a Springer Netherlands |c 2013 | ||
| 300 | |a 111-118 | ||
| 490 | 0 | |a PATHOLOGY AND ONCOLOGY RESEARCH |v 80 No. 3 | |
| 520 | 3 | |a Increased proliferation activity of breast cancer cells evaluated by Ki-67 immunohistochemistry, i.e. a high Ki-67 labeling index (Ki-67 LI), may predict better tumor regression in case of neoadjuvant chemotherapy. Despite recommendations for the evaluation of Ki-67 LI, there are variations in methodology. We assessed the effect of different evaluation methods on the Ki-67 LI in patients with different response to neoadjuvant chemotherapy. Thirty pretreatment core-biopsy samples of patients receiving neoadjuvant docetaxel-epirubicin chemotherapy with or without capecitabine were evaluated for their Ki-67 LI. Pathologic regression was categorized as no regression, partial regression and complete regression, with 10 cases in each category. Three antibodies (MIB1, B56, SP6), 4 observers and 4 methods (counting or estimating on glass slides and counting or estimating on representative digital images) were compared. The Kruskal-Wallis test and analyses of variance were performed to investigate the differences in Ki-67 LIs between different clinical outcomes (tumor regression categories). Breast carcinomas with pathological complete regression had a higher mean Ki-67 LI than tumors not achieving complete regression with any methods, observers and antibodies investigated, although there was a variation between different evaluations in what may represent high proliferation. Estimating the Ki-67 LI on digital images representing the highest proliferation in the core biopsy seemed the best in separating complete responders from non-responders. High Ki-67 LI values were more likely associated with pathological complete regression independently of the method of evaluation used, although the definition of high proliferation is problematic. Estimating the Ki-67 LI may be an adequate method of evaluation. | |
| 700 | 0 | 1 | |a Csörgő Erika |e aut |
| 700 | 0 | 1 | |a Nyári Tibor András |e aut |
| 700 | 0 | 1 | |a Cserni Gábor |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/12829/1/020_Voros_A_Pathobiology_343795.pdf |z Dokumentum-elérés |